InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Phase II Clinical Trial on COVID-19 Patients Commenced 5 May 2020 9:44AM $0.027 $0.420 risen by 1,455.56%
$18 Completion of $3.5m Placement - Appendix 2A 4 May 2020 3:33PM $0.026 $0.420 risen by 1,515.38%
$18 Proposed issue of Securities - MXC 4 May 2020 11:56AM $0.027 $0.420 risen by 1,455.56%
$18 Prospectus 4 May 2020 11:50AM $0.027 $0.420 risen by 1,455.56%
$18 March Quarterly Activity and Cashflow Report 29 Apr 2020 1:03PM $0.026 $0.420 risen by 1,515.38%
$18 Second Ethics Committee Approval for Phase II COVID-19 Trial 28 Apr 2020 10:43AM $0.029 $0.420 risen by 1,348.28%
$18 Proposed issue of Securities - MXC 28 Apr 2020 10:42AM $0.029 $0.420 risen by 1,348.28%
$18 Proposed issue of Securities - MXC 28 Apr 2020 10:41AM $0.029 $0.420 risen by 1,348.28%
$18 MGC Pharma Secures Commitments for $3.5m Placement 28 Apr 2020 10:41AM $0.029 $0.420 risen by 1,348.28%
$18 Trading Halt 24 Apr 2020 9:13AM $0.029 $0.420 risen by 1,348.28%
$18 Successful Research Results for MGC on Glioblastoma 22 Apr 2020 9:46AM $0.030 $0.420 risen by 1,300%
$18 Phase II Clinical Trial on Patients Diagnosed with COVID-19 17 Apr 2020 10:49AM $0.025 $0.420 risen by 1,580%
$18 Pause In Trade 17 Apr 2020 9:43AM $0.025 $0.420 risen by 1,580%
$18 Reinstatement to Official Quotation 15 Apr 2020 1:32PM $0.017 $0.420 risen by 2,370.59%
$18 MGC Pharma Signs Agreement Targeting Anti-Viral Treatments 15 Apr 2020 1:31PM $0.017 $0.420 risen by 2,370.59%
$18 MGC Pharma Listing Rule 10.19 Correction 15 Apr 2020 1:30PM $0.017 $0.420 risen by 2,370.59%
$18 Suspension from Official Quotation 8 Apr 2020 9:28AM $0.017 $0.420 risen by 2,370.59%
$18 MGC Pharma COVID-19 Business and Operations Update 6 Apr 2020 2:35PM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 3 Apr 2020 9:31AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 2 Apr 2020 9:39AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 31 Mar 2020 9:33AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 27 Mar 2020 9:28AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 26 Mar 2020 9:28AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 25 Mar 2020 9:09AM $0.017 $0.420 risen by 2,370.59%
$18 Voluntary Suspension Extension 24 Mar 2020 9:39AM $0.017 $0.420 risen by 2,370.59%

451 - 475 of 818 results

Page 19 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.